Transforming the Fight Against Cancer with Next-Generation Immunotherapy
Driven by Science.
Inspired by Hope.
Our Mission
Our Vision
Our Approach
Harnessing the Power of Plasmacytoid Dendritic Cells to Fight Cancer.
Our proprietary monoclonal antibody reactivates these cells, boosting interferon production and triggering a potent anti-tumor immune attack, even in cancers resistant to current treatments.
Our Technology
Powering a New Era of Cancer Immunotherapy
SlingstoneBio’s approach centers on reprogramming the immune system’s “command center”—the plasmacytoid dendritic cell (pDC)—to mount a more effective attack on cancer.
pDCs are specialized immune cells responsible for detecting viral or bacterial threats and releasing type I interferons (IFNs) to activate natural killer (NK) cells, cytotoxic T cells, and other critical immune effectors. However, in many cancer patients—particularly those unresponsive to current checkpoint inhibitors—pDC function is impaired or suppressed.
At SlingstoneBio, we’ve identified a pDC-specific surface marker (Target X) and developed a first-in-class monoclonal antibody (MabX) that selectively binds to this marker and re-activates pDCs. In doing so, MabX induces the secretion of potent type I IFNs and restores immune system signaling, resulting in:
- Enhanced activation of anti-tumor T cells and NK cells
- Repolarization of immunosuppressive macrophages (M2 to M1)
- Suppression of tumor growth and improved survival in vivo
- Enhanced activation of anti-tumor T cells and NK cells
- Repolarization of immunosuppressive macrophages (M2 to M1)
- Suppression of tumor growth and improved survival in vivo
Our Focus
Why We Fight
Cancer remains one of the leading causes of death worldwide, but for patients diagnosed with hard-to-treat forms—such as those resistant to surgery, chemotherapy, or checkpoint inhibitors—the burden is especially devastating. These cancers progress relentlessly, often with limited treatment options, severe side effects, and little hope for long-term remission.
The impact extends far beyond the patient. Families and caregivers face emotional, physical, and financial stress as they navigate uncertain and often heartbreaking journeys.
Despite advances in oncology, the most challenging cancers continue to elude durable cures.
At SlingstoneBio, we are committed to changing that. Our mission is to develop precision immunotherapies that train the body’s own immune system to recognize and destroy cancer—starting with a dendritic cell immunotherapy platform and expanding into new immune-based approaches. By focusing on the cancers where current treatments fall short, we aim to offer a new path forward: one grounded in science, driven by resilience, and inspired by the people who need us most.
Restoring Hope Where It's Needed Most
We believe every patient—no matter how advanced their diagnosis—deserves more than just time. They deserve real hope. Hope for better outcomes, fewer side effects, and the chance to live fully.
At SlingstoneBio, we are channeling science into solutions that bring that hope to life—not just for patients, but for the families and caregivers who walk this path alongside them. Together, we’re working toward a future where even the hardest cancers can be met with confidence, compassion, and a fighting chance.
Our Pipeline
Pipeline Overview
Our Team
Meet the Team
Investors
Supporters
